Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of a study on genomic drivers The BOSS program: improving the safety of bispecific outpatient step-up dosing for multiple myeloma
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA Interview with Sagar Lonial, MD, FACP from Winship Cancer Institute Of Emory University. Filmed at IMS September 29th, 2023. Global Myeloma Care: Addressing Gaps in Low- and Middle-Income Countries | Craig Cole, MD | #IMS2025
Dr. Paul Richardson presents promising IMS 2025 data on mezigdomide, an oral agent showing high response rates in relapsed Genomic drivers of resistance to anti-BCMA immunotherapies in multiple myeloma
Updates on current research exploring treatment strategies for high-risk smoldering myeloma The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma Key Updates from IMS 2025 | Claudio Cerchione, MD | #IMS2025 Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, shares his approach to considering frailty in
Dr. Joseph Mikhael (IMF Chief Medical Officer) breaks down the biggest takeaways from the International Myeloma Society Limitations of current risk stratification tools for multiple myeloma
Lymphocyte counts may help predict delayed neurotoxicity in patients receiving CAR-T cell therapy for multiple myeloma. In this Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, comments on the management of toxicities IMS 2025 Highlight: Myeloma Treatment Is Changing Fast | Mohamad Mohty, MD, PhD | #IMS2025
At IMS 2025, Mohamad Mohty, MD, PhD, shares the latest updates on quadruplets, transplant debates, MRD-guided maintenance High-Risk Smoldering Myeloma & New Frontline Treatment: What Patients Need to Know | IMS Part 2 of 2 Dr. Rahul Banerjee discusses upcoming revisions to the IMWG response criteria — including less reliance on 24-hour urine tests
IMS 2025 | VJHemOnc Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at
IMS Highlights: Frontline Wins, High-Risk Insights, and What's Next in Myeloma | Part 1 of 2 The role of MRD in guiding maintenance treatment decisions in multiple myeloma IMF Chief Medical Officer Dr. Joseph Mikhael shares the latest lessons on myeloma treatment shared at the 2025 International
IMS-IMWG Consensus Definition of HRMM | Int'l Myeloma Foundation Longer Survival With Better Quality of Life: CAR-T for Multiple Myeloma How is minimal residual disease (MRD) being used in real-world myeloma care? In this presentation from the International
5 Multiple Myeloma Research Highlights: 2024 International Myeloma Society Meeting | For Patients The International Myeloma Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma
Join Dr. Claudio Cerchione as he shares the latest breakthroughs and clinical insights from the 2025 International Myeloma Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current treatment landscape for patients with IMS 2025: Day 1 Features Encouraging Results for Patients with
Stay up to date with the latest developments in relapsed/refractory multiple myeloma from the 22nd IMS Annual Meeting with our live social Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current standard and future of risk stratification in About the 22nd IMS Annual Meeting The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic,
Endogenous immune profiles linked to PFS in patients with RRMM treated with CAR T-cells IMS 2025 Promo Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses mechanisms of resistance and predictors of response to Krina Patel, MD, MSc, co–editor-in-chief of Blood Cancers Today, is section chief and research lead for multiple myeloma (MM) at
Highlights from IMS 2025: progress in the understanding and treatment of precursor conditions In our upcoming Livestream session, Dr. Jesus Berdeja and Dr. Keith Steweart will provide updates on the latest myeloma
Frailty-adapted treatment in newly diagnosed multiple myeloma Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Updates from IMS on CAR-T & Bispecifics in Myeloma | Rahul Banerjee, MD | #IMS2025 At IMS 2025, Dr. Rahul Banerjee (Fred Hutch) shares key updates from other investigators, including long-term cilta-cel outcomes,
Using a Single Cell Approach to Define Mechanisms of Progression | Irene Ghobrial, MD | IMS 2023 The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, comments on the importance of bridging therapy prior to CAR T-cell therapy
Quadruplet regimens in transplant-ineligible NDMM: the new standard of care IMS 2025 Updates with Dr. Alfred Garfall Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses two different types of resistance to
This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) IMS Highlights: Frontline Wins, High-Risk Insights, and What's Next in Myeloma
At IMS 2025, Dr. O'Donnell highlights new insights on quadruplets, maintenance, and the role of MRD in risk-adapted care. The treatment landscape for patients with multiple myeloma at first relapse
IMF Chief Medical Officer Dr. Joseph Mikhael shares the latest research from the 2025 International Myeloma Society meeting in IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023 Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of circulating tumor cells (CTCs) to
Lymphocyte Count Used to Predict Delayed Neurotoxicity in Myeloma CAR-T | Hitomi Hosoya MD #ims25 The evolving definition of high-risk multiple myeloma: new criteria IMS 2025 | Relapsed/refractory multiple myeloma
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, comments on the value of the quadruplet-based regimens The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical,
JCO Article Insights: IMS-IMWG Consensus on High-Risk Multiple Myeloma IMS 2025: Top 6 Presentations With Dr Rahul Banerjee - Cancer At the 2025 International Myeloma Society (IMS) Annual Meeting, Anaïs Schavgoulidze, PharmD, presents new research
5 Multiple Myeloma Research Highlights: 2024 International Myeloma Society Meeting | For Patients Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma
Saurabh Zanwar, MBBS, Mayo Clinic, Rochester, MN, addresses the limitations of current risk stratification tools for multiple Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on the growing recognition of outpatient administration of Anti-CD38–based quadruplet regimens for patients with transplant-ineligible multiple myeloma
Stay up to date with the latest developments in newly diagnosed multiple myeloma from the 22nd IMS Annual Meeting with our live social media Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, comments on the evolving use of measurable residual Time Constraints and Myeloma Treatment Decisions | Arturo Hurtado | #IMS2025
This week, the International Myeloma Society (IMS) is hosting its 22nd Annual Meeting—the world's largest gathering of multiple myeloma researchers and The 22nd International Myeloma Society (IMS) Annual Meeting was held in Toronto, Canada, from September 17-20, 2025. This meeting brought together leading Congress Materials – International Myeloma Society (IMS 2025)
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma Interview with Irene Ghobrial, MD from the Dana Farber Cancer institute. Filmed at IMS September 28th, 2023. The HealthTree
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses strategies to improve CAR T-cell Dr. Craig Cole shares insights from the IMS 2025 meeting on advancing equitable myeloma care in low- and middle-income In multiple myeloma care, timing can play a big role in treatment decisions. At the 2025 International Myeloma Society (IMS)
Diana Cirstea, MD, Massachusetts Cancer Center, Boston, MA, discusses the BOSS program experience in multiple myeloma, Myeloma Society's 22nd Annual Meeting (IMS 2025). What I found to be unique about this year's meeting was that some of the most intriguing
The IRAKLIA trial: isatuximab subcutaneous via OBI versus IV in RRMM Kwee Yong, MD, PhD, FRCP, FRCPath, University College London, London, UK, discusses progress being made in the Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, comments on the potential of combining CELMoDs with T-cell
How MRD Status Is Being Used to Guide Myeloma Treatment Decisions | Ben Derman MD #IMS25 Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the most important research updates from the IMF Chief Medical Officer Dr. Joseph Mikhael discusses the latest updates from the 2025 International Myeloma Society (IMS) Ashley Rosko, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, comments on the importance of
2025 International Myeloma Society Annual Meeting The CELMoD, Mezigdomide, Shows Dramatic Results in Relapsed Myeloma | Paul Richardson, MD | #IMS25 Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares updates
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the Phase III IRAKLIA trial (NCT05405166), International Myeloma Society: Home
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, shares details of a consensus paper to guide FAQs on Multiple Myeloma Highlights From the International Myeloma Society Annual Meeting
IMS 2025 | Newly diagnosed multiple myeloma Using MRD Status to Guide Care after Quad Induction in Myeloma | Elizabeth O'Donnell, MD | #IMS25 A genomic consensus model for high-risk myeloma using NGS | Anais Schavgoulidze, PharmD #ims2025
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Updates from the 2025 International Myeloma Society (IMS) meeting.
22nd IMS Annual Meeting - International Myeloma Society In this JCO Article Insights episode, Michael Hughes summarizes "International Myeloma Society and International Myeloma Considering frailty in myeloma treatment decisions: advice for clinicians
Published in the Journal of Clinical Oncology, the peer-reviewed article, "International Myeloma Society/International Myeloma Working Group Likely Change in IMWG Myeloma Response Criteria : 24-Hour Urine & More | Rahul Banerjee, MD | #IMS25 Meet the Expert Session at IMS 2025: outpatient administration of immunotherapy for myeloma
Risk stratification in smoldering myeloma: current standards and emerging advances The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved The International Myeloma Society Annual meeting.
Ongoing trials for newly diagnosed myeloma in the UK: FiTNESS and iFit Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX, comments on the role of measurable residual disease